Boston Scientific Co. (NYSE:BSX) Shares Acquired by Apollon Wealth Management LLC

Apollon Wealth Management LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 78.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,723 shares of the medical equipment provider’s stock after purchasing an additional 9,111 shares during the quarter. Apollon Wealth Management LLC’s holdings in Boston Scientific were worth $1,198,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bruce G. Allen Investments LLC acquired a new stake in Boston Scientific in the 4th quarter valued at about $28,000. Venturi Wealth Management LLC lifted its position in Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 215 shares in the last quarter. Motco boosted its stake in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 372 shares during the last quarter. Cetera Trust Company N.A purchased a new stake in Boston Scientific in the 4th quarter valued at $43,000. Finally, Asset Dedication LLC increased its stake in shares of Boston Scientific by 42.6% in the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $72.72 on Thursday. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $74.39. The firm has a 50 day moving average of $68.68 and a two-hundred day moving average of $61.74. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $106.69 billion, a PE ratio of 61.11, a P/E/G ratio of 2.51 and a beta of 0.77.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 9,818 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $73.29, for a total value of $719,561.22. Following the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Charles J. Dockendorff sold 3,946 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig sold 9,818 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares in the company, valued at $3,032,300.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 82,330 shares of company stock worth $5,682,434. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of analyst reports. TD Cowen upped their price objective on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Thursday, March 7th. Raymond James raised their price target on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a report on Thursday, April 25th. Evercore ISI upped their price objective on Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. UBS Group raised their target price on Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Finally, StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.